Physician Perceptions on the Use of Antibiotics and Probiotics in Adults: An International Survey in the Asia-Pacific Area.
antibiotic prescriptions
antibiotic resistance
antibiotic-associated diarrhea
microbiota
probiotics
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
06
2021
accepted:
28
09
2021
entrez:
5
11
2021
pubmed:
6
11
2021
medline:
25
11
2021
Statut:
epublish
Résumé
The over-prescription of antibiotics is thought to represent a major threat to public health worldwide and is more frequently observed in some low- and middle-income countries. In the Asia-Pacific region, economic development, health care organization and population demographics are very heterogenous. The objective of this survey was to investigate antibiotic use and probiotic co-prescription among adult patients in this area. An online survey of physicians from seven countries of the Asia-Pacific region (Australia, Japan, Indonesia, India, China, Singapore and South Korea) was performed in 2018. The questionnaire explored current practices of physicians concerning antibiotics and probiotics and factors related to prescribing decisions. A total of 387 general practitioners and 350 gastroenterologists completed the questionnaire. Physicians in Australia, Japan and South-Korea were low prescribers of antibiotics (11% to 19% of visits resulted in an antibiotic prescription), while physicians in Indonesia, India, China and Singapore were high prescribers (41% to 61%). A large majority (85%) of physicians agreed that antibiotics disrupted intestinal microbiota. The rates of co-prescription of probiotics varied from 16% in Japan to 39% in Singapore (overall, 27%). Conditions considered by physicians to be prevented by probiotics were mostly antibiotic-associated diarrhea (62%) and Rates of probiotic co-prescription remain low in many countries although the negative effects of antibiotics on the gut microbiota and the benefits of co-prescribing probiotics are generally known.
Sections du résumé
Background and Aims
The over-prescription of antibiotics is thought to represent a major threat to public health worldwide and is more frequently observed in some low- and middle-income countries. In the Asia-Pacific region, economic development, health care organization and population demographics are very heterogenous. The objective of this survey was to investigate antibiotic use and probiotic co-prescription among adult patients in this area.
Methods
An online survey of physicians from seven countries of the Asia-Pacific region (Australia, Japan, Indonesia, India, China, Singapore and South Korea) was performed in 2018. The questionnaire explored current practices of physicians concerning antibiotics and probiotics and factors related to prescribing decisions.
Results
A total of 387 general practitioners and 350 gastroenterologists completed the questionnaire. Physicians in Australia, Japan and South-Korea were low prescribers of antibiotics (11% to 19% of visits resulted in an antibiotic prescription), while physicians in Indonesia, India, China and Singapore were high prescribers (41% to 61%). A large majority (85%) of physicians agreed that antibiotics disrupted intestinal microbiota. The rates of co-prescription of probiotics varied from 16% in Japan to 39% in Singapore (overall, 27%). Conditions considered by physicians to be prevented by probiotics were mostly antibiotic-associated diarrhea (62%) and
Conclusions
Rates of probiotic co-prescription remain low in many countries although the negative effects of antibiotics on the gut microbiota and the benefits of co-prescribing probiotics are generally known.
Identifiants
pubmed: 34737974
doi: 10.3389/fcimb.2021.722700
pmc: PMC8562691
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
722700Informations de copyright
Copyright © 2021 Ghoshal, Gwee, Holtmann, Li, Park, Simadibrata, Sugano, Cohen and Quigley.
Déclaration de conflit d'intérêts
EQ reports personal fees from Alimentary Health, Biocodex, Salix, Menarini, grants from 4D Pharma and Vibrant, and other from Alimentary Health, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Microbiol. 2016 Dec 15;7:1983
pubmed: 28018315
Crit Rev Food Sci Nutr. 2020 Nov 16;:1-26
pubmed: 33198506
Expert Rev Anti Infect Ther. 2010 May;8(5):555-64
pubmed: 20455684
Am J Gastroenterol. 2006 Apr;101(4):812-22
pubmed: 16635227
Infect Control Hosp Epidemiol. 2018 Jul;39(7):771-781
pubmed: 29695312
BMJ. 2002 Jun 8;324(7350):1345-6
pubmed: 12052785
Aliment Pharmacol Ther. 2015 Oct;42(7):793-801
pubmed: 26216624
J Gastroenterol Hepatol. 2018 Jan;33(1):57-69
pubmed: 28589613
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470
pubmed: 29581252
J Antibiot (Tokyo). 2017 May;70(5):520-526
pubmed: 28246379
Biomed Res Int. 2015;2015:214021
pubmed: 25945327
Curr Opin Pharmacol. 2014 Oct;18:56-60
pubmed: 25254623
Yonsei Med J. 2018 Jan;59(1):4-12
pubmed: 29214770
Open Med. 2013 May 28;7(2):e56-67
pubmed: 24348885
Future Microbiol. 2008 Oct;3(5):563-78
pubmed: 18811240
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Aliment Pharmacol Ther. 2007 Sep 15;26(6):767-78
pubmed: 17767461
J Pediatr Gastroenterol Nutr. 2016 Mar;62(3):495-506
pubmed: 26756877